|
|
Article: Exelixis, Wyeth Enter $158M Agreement For FXR Program.
- Article from:
- BIOWORLD Today
- Article date:
- December 23, 2005
- Author:
CopyrightCOPYRIGHT 2005 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: Karen Pihl-Carey, Staff Writer
Barely two weeks after inking a deal with Bristol-Myers Squibb Co. for liver X receptor (LXR) agonists, Exelixis Inc. signed a similar agreement with Wyeth Pharmaceuticals - this time for compounds that target the farnesoid X receptor (FXR).
South San Francisco-based Exelixis now has major pharmaceutical companies advancing two of the three main preclinical programs acquired in September 2004 through the buyout of San Diego-based X-Ceptor Therapeutics Inc. for $22.3 million. (See BioWorld Today, Sept. 29, 2004.)
Exelixis has already made back that money with the up-front payments from BMS and Wyeth.
...
Related newspaper, magazine, and journal articles:
|
|
Article: EXELIXIS ACQUIRING ARTEMIS IN $23.1M STOCK-SWAP ...
BIOWORLD Today;
April 24, 2001 ;
700+ words
... ... Duyk told BioWorld Today. "The technological ... people here at Exelixis. They contributed ... costs. (See BioWorld Today, Oct. 3, 2000.) Exelixis acquired Agritope ... percent stake in Exelixis. (See BioWorld Today, Sept. 11 ...
|
|